In the PULSE trial, CCTA following PCI for unprotected left main disease failed to reduce the composite primary endpoint of all-cause death, spontaneous MI, unstable angina, or definite or probable ...

The ACC has released a new Expert Consensus Decision Pathway (ECDP) addressing "10 issues for the clinician in tricuspid regurgitation (TR) evaluation and management." Published in JACC, the ECDP ...

The Global Heart Attack Treatment Initiative (GHATI) is dedicated to collaborating, collecting and sharing data, and utilizing tools to improve acute myocardial infarction (AMI) care for your MI ...

As the new year begins, the landscape of cardiovascular medicine is undergoing a remarkable transformation, driven by groundbreaking technologies and innovative approaches that promise to ...

Mavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive ...

Persistent symptoms after an acute pulmonary embolism (PE) may indicate post-pulmonary embolism syndrome (PPES), a condition affecting up to 50% of patients. The most important consideration in ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

The U.S. Food and Drug Administration (FDA) has approved finerenone to treat patients with heart failure (HF) with LVEF ≥40%. The approval was based on results from the FINEARTS-HF trial, presented at ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...

Patients with heart failure (HF) who had an interatrial shunt inserted did not see any significant benefits overall, compared with those who underwent a placebo procedure, after a median 22-month ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

The One Big Beautiful Bill Act (OBBBA) became law on July 4, cutting more than $1 trillion in Medicaid funding and making substantial changes to the federal student loan program. When the U.S. House ...